Bioventix PLC (AIM: BVXP)
London
· Delayed Price · Currency is GBP · Price in GBX 3,184.00
-16.00 (-0.50%)
Jan 22, 2025, 10:41 AM GMT+1
Bioventix Revenue
In the fiscal year ending June 30, 2024, Bioventix had annual revenue of 13.61M GBP with 6.17% growth. Bioventix had revenue of 6.93M in the half year ending June 30, 2024, a decrease of -0.82%.
Revenue
13.61M
Revenue Growth
+6.17%
P/S Ratio
12.28
Revenue / Employee
800.39K
Employees
17
Market Cap
167.03M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 13.61M | 790.36K | 6.17% |
| Jun 30, 2023 | 12.82M | 1.10M | 9.36% |
| Jun 30, 2022 | 11.72M | 788.68K | 7.22% |
| Jun 30, 2021 | 10.93M | 617.01K | 5.98% |
| Jun 30, 2020 | 10.31M | 1.02M | 11.02% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 38.20B |
| GSK plc | 31.31B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| ConvaTec Group | 1.74B |
| Hikma Pharmaceuticals | 2.39B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |